Literature DB >> 29581702

Linear-In-Flux-Expressions Methodology: Toward a Robust Mathematical Framework for Quantitative Systems Pharmacology Simulators.

Sean T McQuade1, Ruth E Abrams2, Jeffrey S Barrett2, Benedetto Piccoli1, Karim Azer2.   

Abstract

Quantitative Systems Pharmacology (QSP) modeling is increasingly used as a quantitative tool for advancing mechanistic hypotheses on the mechanism of action of a drug, and its pharmacological effect in relevant disease phenotypes, to enable linking the right drug to the right patient. Application of QSP models relies on creation of virtual populations for simulating scenarios of interest. Creation of virtual populations requires 2 important steps, namely, identification of a subset of model parameters that can be associated with a phenotype of disease and development of a sampling strategy from identified distributions of these parameters. We improve on existing sampling methodologies by providing a means of representing the structural relationship across model parameters and describing propagation of variability in the model. This gives a robust, systematic method for creating a virtual population. We have developed the Linear-In-Flux-Expressions (LIFE) method to simulate variability in patient pharmacokinetics and pharmacodynamics using relationships between parameters at baseline to create a virtual population. We demonstrate the importance of this methodology on a model of cholesterol metabolism. The LIFE methodology brings us a step closer toward improved QSP simulators through enhanced capture of the observed variability in drug and disease clinical data.

Entities:  

Keywords:  PCSK9 inhibitor therapy; Virtual patient; pharmacodynamics; pharmacokinetics; quantitative systems pharmacology model

Year:  2017        PMID: 29581702      PMCID: PMC5862386          DOI: 10.1177/1177625017711414

Source DB:  PubMed          Journal:  Gene Regul Syst Bio        ISSN: 1177-6250


  17 in total

Review 1.  Next-generation model-based drug discovery and development: quantitative and systems pharmacology.

Authors:  S R B Allerheiligen
Journal:  Clin Pharmacol Ther       Date:  2010-06-09       Impact factor: 6.875

Review 2.  Using quantitative systems pharmacology for novel drug discovery.

Authors:  Violeta I Pérez-Nueno
Journal:  Expert Opin Drug Discov       Date:  2015-08-25       Impact factor: 6.098

3.  Evaluation of HIV-1 and CD4+ T cell dynamic parameters in patients treated with genotypic resistance testing-guided HAART.

Authors:  Antonio Cappuccio; Filippo Castiglione; Benedetto Piccoli; Valerio Tozzi
Journal:  Curr HIV Res       Date:  2008-06       Impact factor: 1.581

4.  Laplacian dynamics on general graphs.

Authors:  Inomzhon Mirzaev; Jeremy Gunawardena
Journal:  Bull Math Biol       Date:  2013-09-10       Impact factor: 1.758

Review 5.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

6.  Integrating epidemiological data into a mechanistic model of type 2 diabetes: validating the prevalence of virtual patients.

Authors:  David J Klinke
Journal:  Ann Biomed Eng       Date:  2007-11-29       Impact factor: 3.934

7.  NIH Support for the Emergence of Quantitative and Systems Pharmacology.

Authors:  M Rogers; P Lyster; R Okita
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-10

8.  A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Authors:  Jeffrey E Ming; Ruth E Abrams; Derek W Bartlett; Mengdi Tao; Tu Nguyen; Howard Surks; Katherine Kudrycki; Ananth Kadambi; Christina M Friedrich; Nassim Djebli; Britta Goebel; Alex Koszycki; Meera Varshnaya; Joseph Elassal; Poulabi Banerjee; William J Sasiela; Michael J Reed; Jeffrey S Barrett; Karim Azer
Journal:  Gene Regul Syst Bio       Date:  2017-06-22

9.  A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation.

Authors:  Mark T Mc Auley; Darren J Wilkinson; Janette J L Jones; Thomas B L Kirkwood
Journal:  BMC Syst Biol       Date:  2012-10-10
View more
  4 in total

1.  A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Authors:  Jeffrey E Ming; Ruth E Abrams; Derek W Bartlett; Mengdi Tao; Tu Nguyen; Howard Surks; Katherine Kudrycki; Ananth Kadambi; Christina M Friedrich; Nassim Djebli; Britta Goebel; Alex Koszycki; Meera Varshnaya; Joseph Elassal; Poulabi Banerjee; William J Sasiela; Michael J Reed; Jeffrey S Barrett; Karim Azer
Journal:  Gene Regul Syst Bio       Date:  2017-06-22

2.  A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.

Authors:  Ruth Abrams; Chanchala D Kaddi; Mengdi Tao; Randolph J Leiser; Giulia Simoni; Federico Reali; John Tolsma; Paul Jasper; Zachary van Rijn; Jing Li; Bradley Niesner; Jeffrey S Barrett; Luca Marchetti; M Judith Peterschmitt; Karim Azer; Susana Neves-Zaph
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-06-19

3.  Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology.

Authors:  Chanchala D Kaddi; Bradley Niesner; Rena Baek; Paul Jasper; John Pappas; John Tolsma; Jing Li; Zachary van Rijn; Mengdi Tao; Catherine Ortemann-Renon; Rachael Easton; Sharon Tan; Ana Cristina Puga; Edward H Schuchman; Jeffrey S Barrett; Karim Azer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-06-19

Review 4.  History and Future Perspectives on the Discipline of Quantitative Systems Pharmacology Modeling and Its Applications.

Authors:  Karim Azer; Chanchala D Kaddi; Jeffrey S Barrett; Jane P F Bai; Sean T McQuade; Nathaniel J Merrill; Benedetto Piccoli; Susana Neves-Zaph; Luca Marchetti; Rosario Lombardo; Silvia Parolo; Selva Rupa Christinal Immanuel; Nitin S Baliga
Journal:  Front Physiol       Date:  2021-03-25       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.